Facilitating clinical studies in rare diseases

8Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.
Get full text

Abstract

In recent years, there have been many scientific advances and new collaborations for rare diseases research and, ultimately, the health of patients living with rare diseases. However, for too many rare diseases, there still is no effective treatment, and our understanding of the incidence, prevalence, and underlying etiology is incomplete. To facilitate the studies needed to answer the many open questions there is a great need for the active involvement of all stakeholders, most importantly of patient groups. Also, the creation of streamlined infrastructure for performing multi-site clinical studies is critical, as is the engagement of multi-disciplinary teams with shared focus on a group of diseases. Another essential component of such efforts is to collect standardized data so that downstream meta-analyses and data sharing can be facilitated. To ensure high-quality protocols and datasets, a central data management and coordinating center is important. Since there are more than 6000 rare diseases, instead of focusing on single rare disease, it is more impactful to create platforms and methods that can support a group of rare diseases.

Cite

CITATION STYLE

APA

Gopal-Srivastava, R., & Kaufmann, P. (2017). Facilitating clinical studies in rare diseases. In Advances in Experimental Medicine and Biology (Vol. 1031, pp. 125–140). Springer New York LLC. https://doi.org/10.1007/978-3-319-67144-4_6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free